NO20001219L - Mixture for drug administration - Google Patents

Mixture for drug administration

Info

Publication number
NO20001219L
NO20001219L NO20001219A NO20001219A NO20001219L NO 20001219 L NO20001219 L NO 20001219L NO 20001219 A NO20001219 A NO 20001219A NO 20001219 A NO20001219 A NO 20001219A NO 20001219 L NO20001219 L NO 20001219L
Authority
NO
Norway
Prior art keywords
mixture
drug administration
drug
composition
approximation
Prior art date
Application number
NO20001219A
Other languages
Norwegian (no)
Other versions
NO20001219D0 (en
Inventor
Lisbeth Illum
Yu-Hui Cheng
Peter James Watts
Stanley Steward Davis
Original Assignee
West Pharm Serv Drug Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by West Pharm Serv Drug Res Ltd filed Critical West Pharm Serv Drug Res Ltd
Publication of NO20001219L publication Critical patent/NO20001219L/en
Publication of NO20001219D0 publication Critical patent/NO20001219D0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Farmasøytisk blanding omfattende polymeriske mikro- partikler, inkludert et medikament og en fettsyre, hvilken blanding kan tilpasses for å gi en fngivelses-hastighet som er tilnærmet lineær med tid, og uten å gi en betydelig sprengeffekt.A pharmaceutical composition comprising polymeric micro-particles, including a drug and a fatty acid, which composition can be adapted to provide a rate of approximation that is approximately linear with time, and without providing a significant bursting effect.

NO20001219A 1997-09-09 2000-03-09 Mixture for drug administration NO20001219D0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9718986.4A GB9718986D0 (en) 1997-09-09 1997-09-09 Controlled release microsphere delivery system
PCT/GB1998/002692 WO1999012549A2 (en) 1997-09-09 1998-09-07 Controlled release microsphere delivery system

Publications (2)

Publication Number Publication Date
NO20001219L true NO20001219L (en) 2000-03-09
NO20001219D0 NO20001219D0 (en) 2000-03-09

Family

ID=10818687

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20001219A NO20001219D0 (en) 1997-09-09 2000-03-09 Mixture for drug administration

Country Status (10)

Country Link
EP (1) EP1011680A2 (en)
JP (1) JP2001515862A (en)
AR (1) AR017079A1 (en)
AU (1) AU745511B2 (en)
CA (1) CA2302762A1 (en)
GB (1) GB9718986D0 (en)
NO (1) NO20001219D0 (en)
NZ (1) NZ502710A (en)
WO (1) WO1999012549A2 (en)
ZA (1) ZA987762B (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6194006B1 (en) 1998-12-30 2001-02-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of microparticles having a selected release profile
US6495166B1 (en) 1999-11-12 2002-12-17 Alkermes Controlled Therapeutics Inc. Apparatus and method for preparing microparticles using in-line solvent extraction
US6331317B1 (en) 1999-11-12 2001-12-18 Alkermes Controlled Therapeutics Ii Inc. Apparatus and method for preparing microparticles
US6705757B2 (en) 1999-11-12 2004-03-16 Alkermes Controlled Therapeutics, Inc. Ii Method and apparatus for preparing microparticles using in-line solvent extraction
ES2169980B1 (en) * 1999-12-17 2003-11-01 Lipotec Sa MICROCAPSULES FOR THE PROLONGED RELEASE OF PHARMACOS.
US6264987B1 (en) 2000-05-19 2001-07-24 Alkermes Controlled Therapeutics Inc. Ii Method for preparing microparticles having a selected polymer molecular weight
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
US6824822B2 (en) 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
US6471995B1 (en) 2000-09-27 2002-10-29 Alkermes Controlled Therapeutics, Inc. Ii Apparatus and method for preparing microparticles using liquid-liquid extraction
US20020114843A1 (en) 2000-12-27 2002-08-22 Ramstack J. Michael Preparation of microparticles having improved flowability
CN1662260B (en) 2002-06-25 2010-04-28 武田药品工业株式会社 Process for producing sustained-release composition
AU2003272011A1 (en) * 2002-10-31 2004-05-25 Pfizer Products Inc. Solid and semi-solid polymeric ionic conjugates
JP4836797B2 (en) 2003-10-23 2011-12-14 大塚製薬株式会社 Controlled release sterile injection aripiprazole formulations and methods
ATE531374T1 (en) 2004-04-15 2011-11-15 Alkermes Inc DELAYED RELEASE POLYMER BASED DEVICE
US20090142404A1 (en) 2004-08-31 2009-06-04 Pfizer Inc Pharmaceutical dosage forms comprising a low-solubility drug and a polymer
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
US7682356B2 (en) 2006-08-09 2010-03-23 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies for use therein
MX2009003737A (en) * 2006-10-05 2009-06-16 Panacea Biotec Ltd Injectable depot composition and it's process of preparation.
CN101563068B (en) 2006-12-18 2013-03-20 武田药品工业株式会社 Sustained-release composition and method for producing the same
JP5351884B2 (en) 2007-04-23 2013-11-27 インターシア セラピューティクス，インコーポレイティド Suspension preparation and use of insulin secretagogue peptide
DK2170279T3 (en) 2007-07-31 2018-03-12 Otsuka Pharma Co Ltd PROCEDURES FOR PREPARING AN ARIPIPRAZOL SUSPENSION AND A FREEZER DRIED FORMULATION
CA2726861C (en) 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
HUE035862T2 (en) 2009-09-28 2018-05-28 Intarcia Therapeutics Inc Rapid establishment and/or termination of substantial steady-state drug delivery
CA2816288C (en) 2010-11-25 2016-01-26 Shandong Luye Pharmaceutical Co., Ltd. Compositions of rotigotine, derivatives thereof, or pharmaceutically acceptable salts of rotigotine or its derivative
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
JO3410B1 (en) 2011-06-07 2019-10-20 Otsuka Pharma Co Ltd Freeze-dried aripiprazole formulation
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
ES2968262T3 (en) 2015-06-03 2024-05-08 I2O Therapeutics Inc Implant placement systems
WO2017200943A1 (en) 2016-05-16 2017-11-23 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
CN110225762A (en) 2017-01-03 2019-09-10 因塔西亚制药公司 The method of the co-administration of continuous administration and drug including GLP-1 receptor stimulating agent
JP2020511483A (en) 2017-03-20 2020-04-16 テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーＴｅｖａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ Sustained-release olanzapine preparation
KR102045721B1 (en) * 2019-03-27 2019-11-18 주식회사 씨트리 Compositions of dispersion phase for preparation of apixaban loaded microsphere and biocompatible polymer based apixaban loaded microsphere prepared therefrom

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4384975A (en) * 1980-06-13 1983-05-24 Sandoz, Inc. Process for preparation of microspheres
US4389330A (en) * 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
GB9009229D0 (en) * 1990-04-25 1990-06-20 Lilly Industries Ltd Pharmaceutical compounds
DK0669128T3 (en) * 1992-11-17 2000-06-19 Yoshitomi Pharmaceutical Sustained-release microsphere containing antipsychotics and method of producing same
IL117612A0 (en) * 1995-03-24 1996-07-23 Lilly Co Eli Granule formulation for olanzapine

Also Published As

Publication number Publication date
WO1999012549A2 (en) 1999-03-18
AR017079A1 (en) 2001-08-22
WO1999012549A3 (en) 1999-05-06
NZ502710A (en) 2001-09-28
EP1011680A2 (en) 2000-06-28
CA2302762A1 (en) 1999-03-18
AU8992598A (en) 1999-03-29
NO20001219D0 (en) 2000-03-09
GB9718986D0 (en) 1997-11-12
ZA987762B (en) 2000-02-28
JP2001515862A (en) 2001-09-25
AU745511B2 (en) 2002-03-21

Similar Documents

Publication Publication Date Title
NO20001219L (en) Mixture for drug administration
DK1032376T3 (en) Use of benzhydrylsulfinyl derivatives for the treatment of sleepiness of medicinal origin
EE03137B1 (en) Veterinary medicinal product and process for its preparation
AU2901489A (en) Onset-hastened/enhanced analgesia using s(+) ketoprofen
AU1992592A (en) Treatment of drug withdrawal symptoms and drug craving with type b monoamine oxidase inhibitors
EP0130779A3 (en) Pharmaceutical composition suitable for intestinal administration
MY111879A (en) Pharmaceutical formulations.
DE69637961D1 (en) ADMINISTRATION OF BIOLOGICALLY ACTIVE POLYPEPTIDES
DK0973413T3 (en) Food formulations containing lacto-N-neotetraose
DK0954290T3 (en) Controlled-release pharmaceutical tablet containing a carrier based on cross-linked amylose and hydroxypropylmethylcellulose
TR199701490A2 (en) 3-Hydroxypyridine-2-carbon acidamidester and their manufacture.
NO942325L (en) Transdermally administered system containing acetylsalicylic acid for thrombosis therapy and cancer prophylaxis
PL330910A1 (en) Mode of administering inhibitors of h+, k+ - atpase
AU6346586A (en) Therapeutic agents
NO955126L (en) Low polyamine food and / or pharmaceutical composition and therapeutic uses thereof
AU4519399A (en) Anti-inflammatory pharmaceutical formulations
AU6889196A (en) Long active composition for rectal administration
CA2140032A1 (en) Cross-linked amylose material for enzymatically controlled drug release
DK0770082T3 (en) Dioxo-thiopyrano-pyridine carboxylic acid derivatives and their use as drugs
PL334093A1 (en) Application of comt inhibitors in production of drugs preventing occurence of vascular disorders in case of diabetes
AU3605995A (en) The use of needle-free pressure-actuated injection devices for the administration of active substances to plants
RU96100906A (en) METHOD FOR RADICAL TREATMENT OF PRIMARY HYPOTHYROIDISM
UA29946A (en) ENTEROSORBENT "FIBROSORB VITA"
UA885A1 (en) Agent for treating gastrointestinal diseases of calves with diarrhea

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application